Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxotere-Mono Study in metastatic NSCLC
2006-001552-12Phase 2Terminated
- Sponsor
- Kliniken Essen-Mitte
- Start
- Sep 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Docetaxel monotherapy with Gemcitabine monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Sep 2006; status: terminated.
02
Drugs
docetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-001552-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001552-12.